At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

VERSANT and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Auto-LiPA 48 and TENDIGO are trademarks of Fujirebio Europe NV. All other trademarks and brands are the property of their respective owners. This product can guide the physician when selecting direct-acting antiviral agents (DAAs). Thus, the assay is intended to be used with samples known to be positive for HCV RNA. The VERSANT HCV Genotype 2.0 Assay (LiPA) is not intended to be used as a screening test for HCV or as a diagnostic test to confirm the presence of HCV.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

CE-marked for IVD use in the EU.
Trusted Results
the First Time

Optimize your laboratory’s testing with the widely used VERSANT® HCV Genotype 2.0 Assay (LiPA).* LiPA utilizes reverse-hybridization technology to detect genotypes 1–6 and 15 subtypes, including 1a, 1b, and 6 (c–l). LiPA provides highly accurate identification of HCV genotypes and subtypes for optimal and personalized patient therapy.

LiPA Enables
Precision Medicine

LiPA results help guide antiviral therapy in patients with chronic hepatitis C virus (HCV) infection and to determine duration and dosage of therapy. The LiPA assay analyzes variations in the 5' untranslated region (5' UTR) and core region to improve accuracy and provide more precise distinction between subtypes 1a and 1b and 6 (c–l).

- HCV infection is a serious public health problem, with an estimated 71 million people infected worldwide. (http://www.who.int/mediacentre/factsheets/fs164/en/)

LiPA Enables
Precision Medicine

- Highly effective HCV treatment regimens including direct antiviral agents (DAA) are now available. These regimens can impact the rate of cured infections.†
- Testing for HCV genotype is recommended to guide selection of the most appropriate antiviral regimen.†
- With certain regimens, patients infected with genotype 1a may have higher rates of virologic failure than those infected with genotype 1b.‡

---

*CE-marked for IVD use in the EU.
Flexible Laboratory Solutions—Only from Siemens Healthineers

1. **Extraction**
   - High-quality RNA for genotyping.
   - Flexible RNA extraction options
     - Manual
     - Automated

2. **Amplification**
   - Easy-to-use, one-step RT-PCR master mix configuration amplifies HCV targets.
   - Amplification and detection flexibility
     - Adaptable to most laboratory validated thermal cyclers
     - Simultaneous amplification of HCV 5’ UTR and core region for accurate detection of genotypes 6 (c–l) and subtypes 1a vs. 1b

3. **Genotyping**
   - Reverse hybridization technology uses 22 genotype- and subtype-specific probes.
   - Scalable strip processing
     - Manual processing
     - Automated TENDIGO™ instrument (delivers up to 10 samples per run)
     - Automated Auto-LiPA 48™ instrument (delivers up to 48 samples per run)

4. **Interpretation**
   - Genotype and subtype are determined from the band pattern using an interpretation chart.
   - Result interpretation options
     - Visual or software-based interpretation of results
     - Easy-to-use interpretation chart
     - Multiple software features and bidirectional LIS compatibility for management of results data

- Contact your regional sales representative for more information on this option.

Compatible with common extraction platforms

Choice of thermal cyclers

TENDIGO Instrument

Auto-LiPA 48 Instrument

LiPA-Scan Software
Perform HCV Genotyping and Subtyping with Greater Accuracy

Proven technology, optimized assay
Based on sequences from the core region and the 5’ UTR, the VERSANT HCV Genotype 2.0 Assay (LiPA) uses reverse hybridization technology to provide accurate identification of HCV genotype- and subtype-specific data for optimal patient therapy.

• Identification of more than 15 different subtypes
• Analysis of 5’ UTR and core regions
• Highly accurate differentiation of subtypes 1a vs. 1b
• Easy-to-use interpretation chart

Optimize Your HCV Testing Efficiency with LiPA

VERSANT LiPA Strips provide convenient and easy interpretation.

Hepatitis C viral RNA genome
Target: HCV 5’ UTR and Core Region

<table>
<thead>
<tr>
<th>5’ UTR</th>
<th>Structural Proteins</th>
<th>Nonstructural Proteins</th>
<th>3’ UTR</th>
</tr>
</thead>
<tbody>
<tr>
<td>5’</td>
<td>Core</td>
<td>E1</td>
<td>E2</td>
</tr>
</tbody>
</table>

Taking the Next Step
Contact your local Siemens Healthineers representative to learn more or visit siemens-healthineers.com/molecular-diagnostics.